FDA Approves Bayer’s Kerendia for Chronic Kidney Disease Associated With Type 2 Diabetes
Bayer’s Kerendia (finerenone) has secured FDA approval for treatment of patients with chronic kidney disease (CKD) associated with type 2 diabetes.
Kerendia is a nonsteroidal mineralocorticoid receptor antagonist intended to slow CKD progression, reduce the risk of kidney failure, heart attack, heart failure hospitalization and cardiovascular death.
The FDA approval comes after a phase 3 trial of 5,674 patients in which Kerendia treatment resulted in a lower risk of CKD progression and cardiovascular events than placebo.
The incidence of CKD is as high as 40 percent among type 2 diabetes patients.